BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 10969976)

  • 1. Cinnamaldehydes inhibit cyclin dependent kinase 4/cyclin D1.
    Jeong HW; Kim MR; Son KH; Han MY; Ha JH; Garnier M; Meijer L; Kwon BM
    Bioorg Med Chem Lett; 2000 Aug; 10(16):1819-22. PubMed ID: 10969976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo [3,4-c] carbazoles as cyclin D1/CDK4 inhibitors.
    Zhu G; Conner S; Zhou X; Shih C; Brooks HB; Considine E; Dempsey JA; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA
    Bioorg Med Chem Lett; 2003 Apr; 13(7):1231-5. PubMed ID: 12657252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.
    Zhu G; Conner SE; Zhou X; Shih C; Li T; Anderson BD; Brooks HB; Campbell RM; Considine E; Dempsey JA; Faul MM; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA
    J Med Chem; 2003 May; 46(11):2027-30. PubMed ID: 12747775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of novel inhibitors of cyclin-dependent kinases.
    Kent LL; Hull-Campbell NE; Lau T; Wu JC; Thompson SA; Nori M
    Biochem Biophys Res Commun; 1999 Jul; 260(3):768-74. PubMed ID: 10403840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.
    Engler TA; Furness K; Malhotra S; Sanchez-Martinez C; Shih C; Xie W; Zhu G; Zhou X; Conner S; Faul MM; Sullivan KA; Kolis SP; Brooks HB; Patel B; Schultz RM; DeHahn TB; Kirmani K; Spencer CD; Watkins SA; Considine EL; Dempsey JA; Ogg CA; Stamm NB; Anderson BD; Campbell RM; Vasudevan V; Lytle ML
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2261-7. PubMed ID: 12824014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dimerization of the amino terminal domain of p57Kip2 inhibits cyclin D1-cdk4 kinase activity.
    Reynaud EG; Guillier M; Leibovitch MP; Leibovitch SA
    Oncogene; 2000 Feb; 19(9):1147-52. PubMed ID: 10713702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors.
    Rossi KA; Markwalder JA; Seitz SP; Chang CH; Cox S; Boisclair MD; Brizuela L; Brenner SL; Stouten PF
    J Comput Aided Mol Des; 2005 Feb; 19(2):111-22. PubMed ID: 16075305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
    Fåhraeus R; Laín S; Ball KL; Lane DP
    Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic approaches to indolo[6,7-a]pyrrolo[3,4-c]carbazoles: potent cyclin D1/CDK4 inhibitors.
    Faul MM; Engler TA; Sullivan KA; Grutsch JL; Clayton MT; Martinelli MJ; Pawlak JM; LeTourneau M; Coffey DS; Pedersen SW; Kolis SP; Furness K; Malhotra S; Al-awar RS; Ray JE
    J Org Chem; 2004 Apr; 69(9):2967-75. PubMed ID: 15104433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors.
    Sanchez-Martinez C; Shih C; Faul MM; Zhu G; Paal M; Somoza C; Li T; Kumrich CA; Winneroski LL; Xun Z; Brooks HB; Patel BK; Schultz RM; DeHahn TB; Spencer CD; Watkins SA; Considine E; Dempsey JA; Ogg CA; Campbell RM; Anderson BA; Wagner J
    Bioorg Med Chem Lett; 2003 Nov; 13(21):3835-9. PubMed ID: 14552791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.
    Barvian M; Boschelli DH; Cossrow J; Dobrusin E; Fattaey A; Fritsch A; Fry D; Harvey P; Keller P; Garrett M; La F; Leopold W; McNamara D; Quin M; Trumpp-Kallmeyer S; Toogood P; Wu Z; Zhang E
    J Med Chem; 2000 Nov; 43(24):4606-16. PubMed ID: 11101352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, crystal structure and biological activity of beta-carboline based selective CDK4-cyclin D1 inhibitors.
    García MD; Wilson AJ; Emmerson DP; Jenkins PR; Mahale S; Chaudhuri B
    Org Biomol Chem; 2006 Dec; 4(24):4478-84. PubMed ID: 17268643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation.
    Anderson M; Beattie JF; Breault GA; Breed J; Byth KF; Culshaw JD; Ellston RP; Green S; Minshull CA; Norman RA; Pauptit RA; Stanway J; Thomas AP; Jewsbury PJ
    Bioorg Med Chem Lett; 2003 Sep; 13(18):3021-6. PubMed ID: 12941325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Aminoquinazoline inhibitors of cyclin-dependent kinases.
    Bathini Y; Singh I; Harvey PJ; Keller PR; Singh R; Micetich RG; Fry DW; Dobrusin EM; Toogood PL
    Bioorg Med Chem Lett; 2005 Sep; 15(17):3881-5. PubMed ID: 15993068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical characterizations reveal different properties between CDK4/cyclin D1 and CDK2/cyclin A.
    Kim DM; Yang K; Yang BS
    Exp Mol Med; 2003 Oct; 35(5):421-30. PubMed ID: 14646596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of selective inhibitors of cyclin dependent kinase 4.
    Carini DJ; Kaltenbach RF; Liu J; Benfield PA; Boylan J; Boisclair M; Brizuela L; Burton CR; Cox S; Grafstrom R; Harrison BA; Harrison K; Akamike E; Markwalder JA; Nakano Y; Seitz SP; Sharp DM; Trainor GL; Sielecki TM
    Bioorg Med Chem Lett; 2001 Aug; 11(16):2209-11. PubMed ID: 11514172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitors.
    Al-awar RS; Ray JE; Hecker KA; Huang J; Waid PP; Shih C; Brooks HB; Spencer CD; Watkins SA; Patel BR; Stamm NB; Ogg CA; Schultz RM; Considine EL; Faul MM; Sullivan KA; Kolis SP; Grutsch JL; Joseph S
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3217-20. PubMed ID: 15149678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.
    Kim KS; Sack JS; Tokarski JS; Qian L; Chao ST; Leith L; Kelly YF; Misra RN; Hunt JT; Kimball SD; Humphreys WG; Wautlet BS; Mulheron JG; Webster KR
    J Med Chem; 2000 Nov; 43(22):4126-34. PubMed ID: 11063609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
    Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
    Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1).
    Cheng M; Sexl V; Sherr CJ; Roussel MF
    Proc Natl Acad Sci U S A; 1998 Feb; 95(3):1091-6. PubMed ID: 9448290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.